Dexmedetomidine
Drug10 minutes loading dose of 0.9 mcg/kg
Maintenance dose of 0.6 mcg/kg/hour
Other names: Dexmedetomidine hydrochloride
NCT Number: NCT00494832
The purposes of this study are:
1. To evaluate the safety and efficacy of Dexmedetomidine as an adjunct for anesthesia during spine surgery and 2. To investigate the influence of Dexmedetomidine on the evoked potentials.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Harborview Medical Center, Seattle, Washington, United States
Use of evoked potentials can significantly improve neurologic outcome after major spine surgery. Modalities of evoked potentials commonly used are Somato-Sensory Evoked Potentials (SSEP's), Motor Evoked Potentials (MEP's), and Visual Evoked Potentials (VEP's).
Dexmedetomidine (DEX) is an alpha-2 agonist and has been FDA approved as an adjunct sedative agent to general anesthesia. It has been purported to reduce the amount of anesthetic required and potentiate the analgesic effect of opiates. In addition, DEX was shown to have minimal effect on SSEP's and VEP's in both rats and humans. Any decrease in the dose of general anesthesia that improves the monitoring of evoked potentials, supports DEX as an adjunct.
It is known that all anesthetic agents can interfere with the recording of evoked potentials. The choice of anesthetic however, depends on the modality of neurophysiologic monitoring planned for the patient. Total intravenous anesthesia (TIVA) and Sevoflurane, a low dose inhalational anesthetic are the usual agents for spine surgery. Both have a dose-related depressant effect on the quality of evoked potentials. As a result, it is common practice for the anesthesiologist to adjust the depth of anesthesia to improve signaling. The use of either anesthetic must accompany continuous infusion of Propofol and an opioid, Remifentanil or Fentanyl. The anesthesiologist then decides whether DEX should be as an adjunct. In our experience, DEX did not impair evoked potentials. In fact, it improved the quality of signals in a few patients. Yet, there are no published data of such effects in medical literature.
We hypothesize that Dexmedetomidine will not influence evoked potentials when used as an adjunct to general anesthesia. Our study is prospective, randomized, double-blinded and will be carried out on a set of anesthetics. We will first evaluate DEX as an adjunct in TIVA, then as an adjunct to Sevoflurane. The probable benefit of DEX may avoid the use of potent inhaled anesthetics which would improve VEP's monitoring. Quality recording of evoked potentials can enhance our ability to detect iatrogenic injury to the spinal cord and vision.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10 minutes loading dose of 0.9 mcg/kg
Maintenance dose of 0.6 mcg/kg/hour
Other names: Dexmedetomidine hydrochloride
10 minutes loading dose of 0.9 mcg/kg
Maintenance dose of 0.6 mcg/kg/hour
Other names: 0.9% Sodium Chloride
Time frame: Duration of surgery
University of Washington
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05887375
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Columbia, Missouri, United States
View Trial DetailsNCT06210061
Dexmedetomidine, Fentanyl
Cairo, Egypt
View Trial DetailsNCT02606695
Spine Surgery
La Jolla, California, United States
View Trial DetailsNCT04473508
AdverseEvent, Morphine
Nîmes, Gard, France
View Trial Details